StockNews.AI
AYTU
StockNews.AI
15 hrs

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

1. Aytu expects major growth from EXXUA launch in Q4 2025. 2. Fiscal 2025 revenue hits $66.4 million, but with a $13.6 million loss.

Earnings
-1.95%Current Return
VS
-0.01%S&P 500
$2.5609/23 04:07 PM EDTEvent Start
$2.5109/24 04:57 AM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The anticipated launch of EXXUA in a promising market could significantly boost revenue, similar to successful pharmaceutical product launches from prior years.

How important is it?

The launch of a new drug in the competitive MDD market signifies crucial growth potential and may influence investor confidence positively.

Why Long Term?

Successful commercialization of EXXUA is projected for Q4 2025, indicating lasting effects on revenue for the subsequent fiscal years.

Related Companies

PFEJNJLLY
Full year fiscal 2025 net revenue of $66.4 million Full year fiscal 2025 net loss of $13.6 million Full year fiscal 2025 adjusted EBITDA1 of $9.2 million $31.0 million cash balance at June 30, 2025 Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market with what the Company believes to be a novel first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD Company to host conference call and webcast today, September 23, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 23, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2025 full year and fourth quarter.

Related News